Background:
Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. In both pre-clinical studies and recent clinical trials, mutations in the PIK3CA gene have been associated with increased sensitivity to inhibitors of the PI3 kinase pathway.
Recommended Use: This test is used to screen for the most common activating mutations in the alpha subunit of PI3 kinase.
Methodology:
PIK3CA mutation screening is performed on DNA from formalin-fixed, paraffin-embedded (FFPE) tumor tissue by Sanger sequencing of exons 9 and 20.
Specimen Requirements:
- A paraffin block or
- 10 unstained sections of tumor (4-5 microns) (15 sections for small biopsies)
Contact Client Services for shipping materials and procedures at (855)535-1522.
A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES. Please include
detailed clinical information.
Test Performed (Days):
Twice per week
Turn Around Time:
10 - 14 days
Shipment Sensitivity Requirements:
- Keep specimen cool during transit. Do not ship on dry ice.
- Please use the cold pack provided in the KDL shipping kit.
- Ship the specimen overnight express, using the FedEx priority overnight label provided.
- Contact Client Services for shipping materials and procedures at (855) 535-1522.
References:
1. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012 Dec;3(12):1566-75.
Additional Info: